Prosthetics of the pulmonary artery valve in children with congenital heart defects: the experience of one center
Authors:
Company: Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
For correspondence: Sign in or register.
Type: Original articles
DOI:
For citation: Lyapin A.A., Tarasov R.S., Ivkin A.A. Prosthetics of the pulmonary artery valve in children with congenital heart defects: the experience of one center. Creative Cardiology. 2026; 20 (1): 137–146 (in Russ.). DOI: 10.24022/1997-3187-2026-20-1-137-146
Received / Accepted: 23.01.2026 / 05.03.2026
Keywords: congenital heart defect pulmonary valve regurgitation pulmonary valve replacement
Abstract
Objective. To evaluate the outcomes of pulmonary valve replacement in the pediatric group during the hospital and remote postoperative periods.
Material and methods. The retrospective study included 25 children (15 boys and 10 girls; median age 139.92±53.39 months) with chronic pulmonary valve insufficiency following prior surgical intervention for congenital heart disease involving the pulmonary valve.
Results. Twenty-five conduits were implanted (5 Contegra, 7 Shelhigh/Pylon, 13 allograft). Mean cardiopulmonary bypass time was 77 minutes, and mean aortic cross-clamp time was 42 minutes. Acute cerebral blood flow disturbance occurred in one child (4%). The maximum pressure gradient across the conduit at discharge was 15 mm Hg. No in-hospital mortality was observed. The length of stay in the intensive care unit was 2 days, and the total hospital stay was 12 days.
Conclusion. Pulmonary valve replacement is the “gold standard” for treating chronic pulmonary regurgitation in children with congenital heart disease, associated with low in-hospital mortality and perioperative complications, reducing heart failure severity. No significant differences in outcomes were found among the three conduit types over a six-month follow- up.
